Physician profile
Edith Garneau
NPI 1407085558
$10,878.54
in general payments reported to CMS, 2019-2025
31 companies · $3,130 in 2025
The $3,130 reported for 2025 was more than what 78% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,213 · 2020: $639 · 2021: $203 · 2022: $1,050 · 2023: $2,330 · 2024: $2,314 · 2025: $3,130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,560 · Education: $213.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,560.14 |
| Education | $213.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,227.59 | 2019-2025 | |
| Amgen INC. | $2,047.14 | 2019-2025 | Evenity, Krystexxa, Prolia |
| Janssen Biotech, INC. | $1,050.87 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Lilly USA, LLC | $689.13 | 2019-2024 | Taltz, Zepbound |
| Ucb, INC. | $656.43 | 2019-2025 | Cimzia, Bimzelx |
| Mallinckrodt Hospital Products INC. | $528.74 | 2023-2025 | Acthar |
| Glaxosmithkline, LLC. | $492.38 | 2019-2025 | Benlysta |
| E.R. Squibb & Sons, L.L.C. | $333.25 | 2019-2025 | Orencia |
| Novartis Pharmaceuticals Corporation | $271.97 | 2019-2025 | |
| Genentech USA, INC. | $229.16 | 2019-2025 | Actemra |
| Pfizer INC. | $165.66 | 2019-2024 | |
| Astrazeneca Pharmaceuticals Lp | $146.59 | 2022-2025 | Saphnelo |
| Sandoz INC. | $128.51 | 2024-2025 | Hyrimoz |
| Organon LLC | $127.38 | 2023-2025 | Renflexis, Hadlima |
| Ani Pharmaceuticals, INC. | $125.79 | 2023-2025 | Purified Cortrophin Gel |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $95.46 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.27 | 2020-2024 | Cyltezo |
| Sobi, INC | $81.70 | 2019-2025 | |
| Hikma Pharmaceuticals USA | $80.26 | 2019-2020 | |
| Horizon Therapeutics Plc | $55.10 | 2019-2020 | |
| Fresenius Kabi USA, LLC | $41.11 | 2023-2024 | Idacio |
| Novo Nordisk INC | $40.15 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $36.70 | 2019 | |
| Mylan Pharmaceuticals INC. | $22.73 | 2021 | |
| Medtronic, INC. | $21.24 | 2022 | |
| Celgene Corporation | $21.08 | 2019 | |
| Corcept Therapeutics | $16.11 | 2019 | |
| Alexion Pharmaceuticals, INC. | $15.99 | 2024 | Ultomiris |
| Xeris Pharmaceuticals, INC. | $15.65 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $15.61 | 2023 | Seglentis |
| Mallinckrodt Enterprises LLC | $14.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edith Garneau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.